Dzaye Omar, Berning Philipp, Razavi Alexander C, Adhikari Rishav, Jha Kunal, Nasir Khurram, Ayers John W, Mortensen Martin Bødtker, Blaha Michael J
Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Department of Medicine, University Hospital Muenster, Münster, Germany.
Front Cardiovasc Med. 2022 Jul 29;9:936651. doi: 10.3389/fcvm.2022.936651. eCollection 2022.
Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiometabolic drugs, including SGLT2i and GLP-1 RA. We aimed to evaluate the use of online search volumes to reflect United States prescription rates. A repeated cross-sectional analysis of Google search volumes and corresponding data from the IQVIA National Prescription Audit (NPA) of pharmacy dispensing of newly prescribed drugs was performed. Monthly data for online searches and prescription between January 1, 2016 and December 31, 2021 were collected for selected SGLT2i and GLP-1 RA. Prescription data for drugs classes (SGLT2i and GLP-1 RA) and individual drugs were calculated as the total of queried data for branded drug names. Trends were analyzed for visual and quantitative correlation as well as predictive patterns. Overall, online searches increased by 157.6% (95% CI: 142.2-173.1%) and 295.2% (95% CI: 257.7-332.6%) for SGLT2i and GLP-1RA between 2016 and 2021. Prescription rates raised by 114.6% (95% CI: 110.8-118.4%) and 221.0% (95% CI: 212.1-229.9%) for SGLT2i and GLP-1RA for this period. Correlation coefficients (range 0.86-0.99) were strongest for drugs with growing number of prescriptions, for example dapagliflozin, empagliflozin, ertugliflozin, dulaglutide, and semaglutide. Online searches might represent an additional tool to monitor the utilization trends of cardiometabolic drugs. Associations were strongest for drugs with reported cardioprotective effect. Thus, trends in online searches complement conventionally acquired data to reflect and forecast prescription trends of cardiometabolic drugs.
多项临床试验表明，许多钠-葡萄糖协同转运蛋白2抑制剂（SGLT-2i）和胰高血糖素样肽-1受体激动剂（GLP-1 RA）可降低2型糖尿病和动脉粥样硬化性心血管疾病患者发生心血管事件的风险。近期报告指出，包括SGLT-2i和GLP-1 RA在内的新型心脏代谢药物未得到充分利用。我们旨在评估在线搜索量能否反映美国的处方率。对谷歌搜索量以及来自IQVIA全国处方审计（NPA）的新处方药药房配药相应数据进行了重复横断面分析。收集了2016年1月1日至2021年12月31日期间选定的SGLT-2i和GLP-1 RA的在线搜索和处方月度数据。药物类别（SGLT-2i和GLP-1 RA）和个别药物的处方数据计算为品牌药名查询数据的总和。分析了趋势的视觉和定量相关性以及预测模式。总体而言，2016年至2021年期间，SGLT-2i和GLP-1 RA的在线搜索量分别增加了157.6%（95%置信区间：142.2 - 173.1%）和295.2%（95%置信区间：257.7 - 332.6%）。同期，SGLT-2i和GLP-1 RA的处方率分别提高了114.6%（95%置信区间：110.8 - 118.4%）和221.0%（95%置信区间：212.1 - 229.9%）。对于处方数量不断增加的药物，如达格列净、恩格列净、依鲁格列净、度拉糖肽和司美格鲁肽，相关系数最强（范围为0.86 - 0.99）。在线搜索可能是监测心脏代谢药物使用趋势的另一种工具。对于具有心脏保护作用报道的药物，关联最强。因此，在线搜索趋势补充了传统获取的数据，以反映和预测心脏代谢药物的处方趋势。
